JBF Capital’s Harvard Bioscience HBIO Stock Holding History

JBF Capital’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-620	Closed	-$16K	–	68
2017 Q2	$16K	Hold	620	–	–	﹤0.01%	97
2017 Q1	$16K	Buy	+620	New	+$17.9K	﹤0.01%	97
2016 Q3	–	Sell	-620	Closed	-$18K	–	90
2016 Q2	$18K	Hold	620	–	–	﹤0.01%	107
2016 Q1	$19K	Hold	620	–	–	﹤0.01%	117
2015 Q4	$22K	Hold	620	–	–	﹤0.01%	110
2015 Q3	$23K	Hold	620	–	–	﹤0.01%	114
2015 Q2	$35K	Hold	620	–	–	﹤0.01%	87
2015 Q1	$36K	Hold	620	–	–	0.01%	55
2014 Q4	$35K	Hold	620	–	–	0.01%	60
2014 Q3	$25K	Hold	620	–	–	﹤0.01%	49
2014 Q2	$28K	Hold	620	–	–	﹤0.01%	77
2014 Q1	$29K	Hold	620	–	–	﹤0.01%	83
2013 Q4	$29K	Buy	+620	New	+$27.1K	﹤0.01%	81

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPC

Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Foundry Partners Minneapolis, Minnesota $1.89B AUM 9.84% 1-Year Est. Return

JBF Capital's HBIO Position: Q3 2017 in Review

JBF Capital sold out of Harvard Bioscience (HBIO) in Q3 2017, closing a stake of 620 shares — an estimated $16K sold.

JBF Capital first reported a position in HBIO in Q4 2013 and held it in 13 quarters. The position peaked at $36K in Q1 2015. 53 funds tracked by Wall St. Rank hold HBIO as of Q3 2017.

JBF Capital reported no remaining Harvard Bioscience position as of Q3 2017 after selling out during the quarter.
JBF Capital sold 620 Harvard Bioscience shares in Q3 2017, an estimated $16K.
JBF Capital first reported a position in Harvard Bioscience in Q4 2013 and held it in 13 quarters.
JBF Capital's Harvard Bioscience position peaked at $36K in Q1 2015.
53 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2017.

Based on JBF Capital's 13F filing for Q3 2017, filed 13 Nov 2017.